Novo Integrated Sciences, Inc.: Nasdaq/NYSE listing notice — Nasdaq to file Form 25 completing delisting of Novo Integrated Sciences; stock continues on OTC

Novo Integrated Sciences, Inc.

On April 28, 2025, Nasdaq notified Novo Integrated Sciences it will file Form 25 to finalize delisting; effective 10 days after filing.
Company previously received delisting notice and began trading on OTC Market under 'NVOS' on November 6, 2024.
Delisting is due to failure to meet Nasdaq minimum bid price requirement under Listing Rule 5550(a)(2).
Stock will continue to be quoted on OTC Market after Form 25 is filed and becomes effective.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Novo Integrated Sciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 6, 2024. Beginning at the open of trading on November 6, 2024, the Company’s common stock began trading on the OTC Market under the symbol “NVOS.” On April 28, 2025, Nasdaq notified the Company that it would file a Form 25 with the Securities and Exchange Commission to complete the delisting of the Company’s common stock. As of the filing time of this Current Report on Form 8-K, the Form 25 has not yet been filed by Nasdaq. The delisting will be effective 10 days after the Form 25 is filed. The Company’s common stock will continue to be quoted on the OTC Market following filing and ef

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001641172-25-008349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.